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nymOBJECTIVES The aim of this study was to investigate the clinical outcomes of patients deferred from coronary
revascularization on the basis of instantaneous wave-free ratio (iFR) or fractional ﬂow reserve (FFR) measurements in
stable angina pectoris (SAP) and acute coronary syndromes (ACS).
BACKGROUND Assessment of coronary stenosis severity with pressure guidewires is recommended to determine the
need for myocardial revascularization.
METHODS The safety of deferral of coronary revascularization in the pooled per-protocol population (n ¼ 4,486)
of the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation) and
iFR-SWEDEHEART (Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Patients With Stable Angina
Pectoris or Acute Coronary Syndrome) randomized clinical trials was investigated. Patients were stratiﬁed according to
revascularization decision making on the basis of iFR or FFR and to clinical presentation (SAP or ACS). The primary
endpoint was major adverse cardiac events (MACE), deﬁned as the composite of all-cause death, nonfatal myocardial
infarction, or unplanned revascularization at 1 year.
RESULTS Coronary revascularization was deferred in 2,130 patients. Deferral was performed in 1,117 patients (50%) in
the iFR group and 1,013 patients (45%) in the FFR group (p < 0.01). At 1 year, the MACE rate in the deferred population
was similar between the iFR and FFR groups (4.12% vs. 4.05%; fully adjusted hazard ratio: 1.13; 95% conﬁdence interval:
0.72 to 1.79; p ¼ 0.60). A clinical presentation with ACS was associated with a higher MACE rate compared with SAP in
deferred patients (5.91% vs. 3.64% in ACS and SAP, respectively; fully adjusted hazard ratio: 0.61 in favor of SAP; 95%
conﬁdence interval: 0.38 to 0.99; p ¼ 0.04).
CONCLUSIONS Overall, deferral of revascularization is equally safe with both iFR and FFR, with a low MACE rate
of about 4%. Lesions were more frequently deferred when iFR was used to assess physiological signiﬁcance.
In deferred patients presenting with ACS, the event rate was signiﬁcantly increased compared with SAP at 1 year.
(J Am Coll Cardiol Intv 2018;11:1437–49) © 2018 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
CI = conﬁdence interval
FFR = fractional ﬂow reserve
HR = hazard ratio
iFR = instantaneous wave-free
ratio
MACE = major adverse cardiac
event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
SAP = stable angina pectoris
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1441P hysiology-guided coronary revascularizationis currently recommended in clinical practiceguidelines on the grounds of ample evidence
supporting its clinical value (1). Compared with angi-
ography alone, decision making using fractional ﬂow
reserve (FFR) improves patient outcomes and proce-
dural cost efﬁciencies (2). These beneﬁts are due
largely to deferral of myocardial revascularization in
hemodynamically nonsigniﬁcant stenosis (3–5). The
15-year follow-up of the DEFER (Deferral vs. Perfor-
mance of Percutaneous Coronary Intervention of
Functionally Non-Signiﬁcant Coronary Stenosis) trial,
the pivotal study assessing the safety of FFR-based
revascularization deferral, has shown favorable very
long term outcomes (4). However, the results of that
study are difﬁcult to translate into current clinical
practice because of the small sample size, the use of
a different FFR cutoff (0.75), and major developments
in percutaneous coronary intervention (PCI) and
medical therapy in the intervening 17 years (3).SEE PAGE 1450Recently, 2 large randomized clinical trials,
DEFINE-FLAIR (Functional Lesion Assessment of In-
termediate Stenosis to Guide Revascularisation) and
iFR-SWEDEHEART (Instantaneous Wave-Free Ratio
Versus Fractional Flow Reserve in Patients With
Stable Angina Pectoris or Acute Coronary Syndrome),
compared the clinical outcomes of 4,529 patients with
coronary stenoses undergoing either FFR-based or
instantaneous wave-free ratio (iFR)–based revascu-
larization, the latter a novel adenosine-free index of
stenosis severity (6,7). The combined dataset of both
studies provides a unique opportunity to revisit the
safety of physiology-guided deferral of revasculari-
zation in contemporary clinical practice, with the
added value of depicting the predominant clinical
use of FFR, which is interrogation of stenoses with
intermediate angiographic severity (8–10).
In this study, we investigated the 1-year clinical
outcomes of patients who were included in the per-
protocol populations of the DEFINE-FLAIR and iFR-
SWEDEHEART randomized trials. As both trials
included patients with stable angina pectoris (SAP)
and acute coronary syndromes (ACS), the safety of
revascularization deferral in both clinical scenarios
could be compared. This may shed light on conﬂicting
reports regarding the comparable safety of revascu-
larization deferral in patients in stable condition and
in those presenting with ACS (11–15).
METHODS
STUDY DESIGN. The DEFINE-FLAIR and iFR-
SWEDEHEART trial designs have been previouslyDownloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGA
For personal use only. No other uses withoureported (6,7). In brief, both are multicenter,
prospective, randomized trials comparing
clinical outcomes and cost-effectiveness
of iFR- and FFR-based decision making
in physiologically guided coronary revascu-
larization. Eligible patients were randomly
assigned to undergo revascularization deci-
sion making guided by either iFR or FFR.
Patients enrolled in iFR-SWEDEHEART were
included in the SCAAR (Swedish Coronary
Angiography and Angioplasty Registry),
which was used to obtain immediate and
continuous feedback on processes and
quality-of-care measures (Online Appendix).
Whereas iFR-SWEDEHEART had an open-
label design, DEFINE-FLAIR was a double-
blind trial with patients and follow-up teams blinded
to the use of iFR or FFR. Both trials conﬁrmed their
primary hypothesis, that iFR was noninferior to FFR
for major adverse cardiac events (MACE) at 1 year in
patients undergoing physiologically guided revascu-
larization decision making.
STUDY POPULATION. Our study combined and
analyzed the merged populations of the DEFINE-
FLAIR and iFR-SWEDEHEART randomized clinical
trials. These patients had an indication for physio-
logical assessment of at least 1 coronary lesion in
which the functional severity was questionable (40%
to 80% stenosis by visual assessment). This study
included patients with SAP and ACS (unstable angina
pectoris, non–ST-segment elevation myocardial
infarction [MI], and ST-segment elevation MI). In
patients with SAP, any lesion could be assessed. In
patients with ACS, physiological interrogation was
performed only in the nonculprit artery once the
culprit vessel was revascularized. In the case of
ST-segment elevation MI, nonculprit vessels were
evaluated >48 h after primary PCI. Inclusion and
exclusion criteria are listed in the Online Appendix.
In both trials, all participants provided written
informed consent before enrollment.
PROCEDURE. Physiological measurements were per-
formed in the usual manner using the same coronary
pressure guidewire (Verrata, Philips Volcano, San
Diego, California). Before measurement, intra-
coronary nitrates were administered to control vaso-
motor tone. Pre-speciﬁed treatment thresholds were
0.89 for iFR and 0.80 for FFR. Stenoses were revas-
cularized with either PCI or coronary artery bypass
grafting. When iFR or FFR exceeded these pre-
speciﬁed thresholds, treatment was deferred. Pres-
sure drift was assessed using the pressure ratio at the
catheter tip after each physiological measurement.L - Hospital Prof Dr Fernando Fonseca from ClinicalKey.com by Elsevier on January 24, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
FIGURE 1 Flowchart of the Study
* deferral/treated status unknown for 6 patients
** disease type unknown for 15 patients among deferred patients
DEFINE-FLAIR trial
2492 patients included
iFR-SWEDEHEART trial
2037 patients included
4486 patients were analyzed
2350 patients* were
treated according to 
pressure wire
In 2130 patients* PCI was
deferred based on pressure
wire(iFR ≥0.90 or FFR >0.80)
440** patients
presented with ACS
1675** patients
presented with SAP
222 patients were
assessed with iFR
885 patients were
assessed with iFR
218 patients were
assessed with FFR
790 patients were
assessed with FFR
43 patients were
excluded
-protocol violations: 29
-technical issues: 8
-other: 6
A combined total of 4,529 participants were enrolled in the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide
Revascularisation) and iFR-SWEDEHEART (Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Patients With Stable Angina
Pectoris or Acute Coronary Syndrome) randomized clinical trials. ACS ¼ acute coronary syndrome(s); FFR ¼ fractional ﬂow reserve; iFR ¼
instantaneous wave-free ratio; PCI ¼ percutaneous coronary intervention; SAP ¼ stable angina pectoris.
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Downloaded for AnoIf the pressure ratio exceeded 0.02, physiological
measurements were repeated. For patients assigned
to FFR, hyperemia was obtained with intravenous or
intracoronary hyperemic agents as previously
described (6,7). When multivessel revascularization
was required, investigators could stage procedures
within 60 days of the index measurement. Revascu-
larization was performed according to standard clin-
ical practice, with pharmacological therapy left to the
discretion of the treating physician.
ENDPOINTS. The primary safety endpoint of the
study was the composite of MACE, deﬁned as
all-cause death, nonfatal MI, or unplanned revascu-
larization within 12 months of the index procedure.
Secondary endpoints were the individual compo-
nents of MACE. In both DEFINE-FLAIR and iFR-
SWEDEHEART, death and MI were adjudicated with
anonymized source documentation by independent
clinical event adjudication committees, whose mem-
bers were unaware of the group assignments. A
consensus decision was made on the basis of the
pre-speciﬁed endpoint deﬁnitions. Unplanned
revascularization events and secondary angiographicnymous User (n/a) at CONSORTIUM OF PORTUGAL - Hospital Prof Dr Fe
For personal use only. No other uses without permission. Copyrightoutcomes were adjudicated by the clinical event
adjudication committee in DEFINE-FLAIR and by an
independent experienced observer who was unaware
of the group assignments in iFR-SWEDEHEART.
STATISTICAL ANALYSIS. The objective of this study
was to compare event rates between physiological
techniques (iFR vs. FFR) in patients for whom
revascularization was deferred on the grounds of
physiological measurements. Additionally, we inves-
tigated whether clinical presentation (SAP vs. ACS)
inﬂuenced event rates and subsequently if this was
modiﬁed by which physiological technique was used
to guide decision making.
For MACE and its components, a time-to-event
analysis was performed in the per-protocol popula-
tion by Cox survival modeling. Participants who
withdrew from the study before reaching 1 year of
follow-up and who were event free at their last visit
were censored at their time of last visit. Testing of
the validity of the proportional hazards assumption
was done using Schoenfeld residuals. There were no
signs of violations of proportional hazards
assumption.rnando Fonseca from ClinicalKey.com by Elsevier on January 24, 2019.
 ©2019. Elsevier Inc. All rights reserved.
TABLE 1 Baseline Characteristics of the Deferred Population
iFR
(n ¼ 1,117)
FFR
(n ¼ 1,013) p Value
Age (yrs) 66.1  10.7 66.6  9.9 0.55
Male 72.0 (804) 68.0 (689) 0.05
Body mass index (kg/m2) 27.5  4.7 27.5  5.0 0.51
Diabetes mellitus 21.8 (243) 24.8 (251) 0.19
Hypertension 71.1 (794) 71.7 (726) 0.32
Hyperlipidemia 68.5 (765) 66.3 (672) 0.52
Current smoker 19.0 (212) 17.8 (180)
Previous MI 30.1 (336) 30.4 (308) 0.09
Previous PCI 42.6 (476) 43.4 (440) 0.57
CCS angina class <0.01
I 26.8 (299) 22.5 (228)
II 32.8 (366) 27.9 (283)
III 4.8 (54) 7.8 (79)
IV 1.8 (20) 2.3 (23)
Clinical presentation 0.36
Acute coronary syndrome 19.9 (222) 21.5 (218)
Stable angina pectoris 79.2 (885) 78.0 (790)
No information 0.9 (10) 0.5 (5)
Values are mean  SD or % (n).
CCS ¼ Canadian Cardiovascular Society; FFR ¼ fractional ﬂow reserve; iFR ¼
instantaneous wave-free ratio; MI ¼ myocardial infarction; PCI ¼ percutaneous
coronary intervention.
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1443Results are reported using hazard ratios (HRs), 95%
2-sided conﬁdence intervals (CIs), and cumulative
hazard curves. Analyses were performed in an unad-
justed manner as well as adjusted for the following
baseline characteristics that were chosen a priori for
their known associations with cardiovascular events:
age, sex, body mass index, clinical presentation,FIGURE 2 Distribution of Physiological Values
Histograms of FFR (left) and iFR (right) values in the deferred pooled p
Abbreviations as in Figure 1.
Downloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGA
For personal use only. No other uses withouCanadian Cardiovascular Society class for grading of
angina pectoris, diabetes, hypertension, hyperlipid-
emia, smoking status, previous MI, and previous PCI.
Fully adjusted results are presented in the text and
both unadjusted and fully adjusted in the tables.
RESULTS
STUDY POPULATION. A combined total of 4,529
participants were enrolled in both trials; 2,261 were
assigned to the iFR group and 2,268 to the FFR group
(Figure 1). Data for 43 patients were excluded from the
analyses because of unacceptable side effects associ-
ated with adenosine, technical issues, incorrect group
assignment, or other reasons; data for the remaining
4,486 patients were included in the analyses.
BASELINE CHARACTERISTICS. In the overall study
population, the mean age was 66.3 years, 26.6% of
patients had diabetes mellitus, 72.2% had SAP, and
31.0% had history of MI. No differences were found in
baseline characteristics between the iFR and FFR
groups (Online Table 1).
Coronary revascularization was deferred in 2,130
patients. Deferral was performed in 1,117 patients
(50%) in the iFR group and 1,013 patients (45%) in the
FFR group (p < 0.01). The baseline characteristics of
patients deferred by iFR and FFR methods are dis-
played in Table 1. The iFR group included a higher
proportion of male patients than the FFR group
(72.0% vs. 68.0%; p ¼ 0.05). Canadian Cardiovascular
Society grading of angina pectoris was signiﬁcantly
higher in the iFR group (26.8% in class I and 32.8% inatient population of the DEFINE-FLAIR and iFR-SWEDEHEART randomized clinical trials.
L - Hospital Prof Dr Fernando Fonseca from ClinicalKey.com by Elsevier on January 24, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
TABLE 2 Procedural Characteristics of the Deferred Population
iFR
(n ¼ 1,117)
FFR
(n ¼ 1,013) p Value
Site of access 0.60
Radial 76.2 (851) 75.2 (762)
Procedure time (min) 0.02
Median 30 34
Interquartile range 20–45 24–48
Total number of vessels
evaluated
1,478 1,317
Mean iFR/FFR value 0.95  0.03 0.89  0.05
Values are % (n) or mean  SD, unless otherwise indicated.
Abbreviations as in Table 1.
TABLE 3 Time-to-Ev
Components Accordin
Acute Coronary Syndr
MACE
All-cause death
Cardiovascular death
Noncardiovascular deat
Myocardial infarction
Unplanned
revascularization
Values are % (n), unless o
ACS ¼ acute coronary sy
event(s); SAP ¼ stable ang
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Downloaded for Anoclass II) than in the FFR group (22.5% in class I and
27.9% in class II) (p < 0.01 for the difference between
groups). The remaining baseline characteristics were
otherwise well balanced between the iFR- and FFR-
deferred groups.
When the deferred population was stratiﬁed ac-
cording to clinical presentation, overall less lesions
were deferred in ACS compared with clinical presen-
tation with SAP (36% vs. 50%; p < 0.001). In SAP, more
lesions were deferred with iFR than FFR (55% vs.
48%; p < 0.001). In ACS, deferral rates were similar for
both iFR and FFR guidance (36% vs. 36%; p ¼ 0.91).
PROCEDURAL CHARACTERISTICS. In the deferred
population, mean iFR was 0.95  0.03 and mean FFR
was 0.89  0.05. The distribution of iFR and FFR
values is displayed in Figure 2. The procedural char-
acteristics for the deferred populations are displayed
in Table 2. The numbers of physiological evaluations
per patient were 1.32  0.67 for iFR and 1.30  0.62 for
FFR (p ¼ 0.67). Total procedure time was signiﬁcantly
shorter in the iFR group (median 30 min; interquartileent Analysis for Major Adverse Cardiac Events and Their
g to Clinical Presentation (Stable Angina Pectoris Versus
omes) in Deferred Patients
SAP
(n ¼ 1,675)
ACS
(n ¼ 440)
SAP vs. ACS
p Value
Unadjusted HR
(95% CI)
Fully Adjusted
HR (95% CI)
3.64 (61) 5.91 (26) 0.62 (0.39–0.99) 0.61 (0.38–0.99) 0.04
0.66 (11) 1.36 (6) 0.50 (0.19–1.36) 0.44 (0.16–1.23) 0.12
0.18 (3) 0.45 (2) 0.41 (0.07–2.45) 0.21 (0.02–1.71) 0.14
h 0.48 (8) 0.91 (4) 0.55 (0.16–1.82) 0.46 (0.13–1.59) 0.22
0.90 (15) 2.50 (11) 0.34 (0.16–0.76) 0.36 (0.16–0.79) 0.01
2.87 (48) 3.64 (16) 0.81 (0.46–1.43) 0.83 (0.46–1.49) 0.53
therwise indicated.
ndrome(s); CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼major adverse cardiac
ina pectoris.
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min; interquartile range: 24 to 48 min) (p ¼ 0.02).
PRIMARY ENDPOINT AND COMPONENTS. There was
no censoring before 12 months in iFR-SWEDEHEART;
150 patients (6.1% of 2,467) in DEFINE-FLAIR volun-
tarily withdrew from the study before 12 months and
were censored at the time of their last visit. In the
overall study population, at 1 year, the primary
endpoint had occurred in 145 of 2,240 patients
(6.47%) in the iFR group and in 144 of 2,246 (6.41%)
in the FFR group (unadjusted HR: 1.03; 95% CI: 0.81
to 1.31; p ¼ 0.81) (Online Figure 1). No signiﬁcant
differences were noted in terms of the components of
the primary endpoint in both study arms (Online
Table 2). The number of deaths from any cause at 12
months did not differ signiﬁcantly between the iFR
group (36 deaths, including 15 from cardiovascular
causes) and the FFR group (25 deaths, including 10
from cardiovascular causes) (p ¼ 0.14). The rates of
nonfatal MI and unplanned revascularization did not
differ signiﬁcantly between the 2 groups.
When stratiﬁed according to clinical presentation,
the overall MACE rate in patients with ACS (7.7%) was
higher than in patients with SAP (6.0%) (fully
adjusted HR: 0.72 in favor of SAP; 95% CI: 0.55 to
0.93; p ¼ 0.01) (Online Table 3). In the deferred pop-
ulation, this difference was driven mainly by a higher
1-year MACE rate among the deferred patients with
ACS (26 of 440 [5.9%]) compared with deferred pa-
tients with SAP (61 of 1,675 [3.6%]) (fully adjusted HR:
0.61 in favor of SAP; 95% CI: 0.38 to 0.99; p ¼ 0.04)
(Table 3).
In the deferred population, at 1 year, the primary
endpoint occurred in 46 of 1,117 patients (4.12%) in
the iFR group and in 41 of 1,013 patients (4.05%) in
the FFR group (fully adjusted HR: 1.13; 95% CI: 0.72 to
1.79; p ¼ 0.60) (Figure 3). The HRs for the individual
components of MACE for iFR- versus FFR-guided
deferral are displayed in Table 4. Unplanned revas-
cularization was the biggest contributor numerically
to the total MACE rate for both iFR- and FFR-deferred
groups (2.78% and 3.26%, respectively; p ¼ 0.63).
There were no signiﬁcant differences in the compo-
nents of MACE between the 2 physiological
techniques.
Within the deferred group, the MACE rate was
more inﬂuenced by clinical presentation in patients
evaluated with FFR (unadjusted HR: 0.52 in favor of
SAP; 95% CI: 0.27 to 1.00; p < 0.05) than in those
evaluated with iFR (unadjusted HR: 0.74 in favor of
SAP; 95% CI: 0.38 to 1.43; p ¼ 0.37) (Table 5), with a
statistically nonsigniﬁcant interaction (Figure 4). The
effect of clinical presentation on MI rate was morernando Fonseca from ClinicalKey.com by Elsevier on January 24, 2019.
 ©2019. Elsevier Inc. All rights reserved.
TABLE 4 Outcomes in the Overall Deferred Population According to
Instantaneous Wave-Free Ratio or Fractional Flow Reserve
iFR
(n ¼ 1,117)
FFR
(n ¼ 1,013)
iFR vs. FFR
p Value
Unadjusted
HR (95% CI)
Fully Adjusted
HR (95% CI)
MACE 4.12 (46) 4.05 (41) 1.05 (0.69–1.60) 1.13 (0.72–1.79) 0.60
All-cause death 0.98 (11) 0.59 (6) 1.68 (0.62–4.55) 2.21 (0.68–7.13) 0.19
Cardiovascular death 0.36 (4) 0.10 (1) 3.66 (0.41–32.76) 2.53 (0.23–28.32) 0.45
Noncardiovascular death 0.63 (7) 0.49 (5) 1.29 (0.41–4.05) 2.04 (0.51–8.13) 0.31
Myocardial infarction 1.16 (13) 1.28 (13) 0.99 (0.45–2.18) 1.00 (0.44–2.28) 1.00
Unplanned
revascularization
2.78 (31) 3.26 (33) 0.86 (0.53–1.40) 0.88 (0.52–1.49) 0.63
Values are % (n), unless otherwise indicated.
Abbreviations as in Tables 1 and 3.
FIGURE 3 Cumulative Risk for Primary Endpoint (Major Adverse Cardiac Events) by
Physiological Technique in the Deferred Population
Shown is the cumulative risk for the composite of death from any cause, nonfatal
myocardial infarction, or unplanned revascularization at 1 year. MACE ¼ major adverse
cardiac event(s); other abbreviations as in Figure 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 1 , N O . 1 5 , 2 0 1 8 Escaned et al.
A U G U S T 1 3 , 2 0 1 8 : 1 4 3 7 – 4 9 Pooled Analysis of DEFINE-FLAIR and iFR-SWEDEHEART
1445marked in the FFR group (unadjusted HR: 0.28 in
favor of SAP; 95% CI: 0.09 to 0.88) than in the iFR
group (unadjusted HR: 0.42 in favor of SAP; 95% CI:
0.14 to 1.27), but the interaction was not statistically
signiﬁcant.
DISCUSSION
The present study demonstrates that the revascular-
ization of intermediate stenoses in patients with SAP
can be safely deferred on the grounds of iFR or FFR
measurements. In patients with ACS, deferral was
associated with more cardiovascular events at follow-
up, compared to patients with SAP.
DEFERRAL OF REVASCULARIZATION: A KEY ASPECT
OF PHYSIOLOGY-GUIDED REVASCULARIZATION.
Physiology-guided revascularization is the current
main application of coronary physiology in the
catheterization laboratory. It aims to improve pa-
tient outcomes by restricting revascularization to
stenoses that cause myocardial ischemia (2,16).
Because coronary angiography is an inadequate
diagnostic tool for estimating functional stenosis
severity, particularly in intermediate stenoses (17),
the predominant role of intracoronary physiology is
to serve as a gatekeeper to revascularization in in-
termediate stenoses (18).
The pivotal DEFER trial, in which 92 of the 325
patients included were randomized to PCI deferral,
consolidated the concept that FFR-based post-
ponement of revascularization is safe (3). However,
translation of the trial to contemporary clinical
practice is hampered not only by the fact that the
0.75 FFR cutoff in the study has been abandoned
from treatment guidelines but also primarily by the
evolution of treatment over the past 20 years:
balloon angioplasty as a stand-alone therapy has
virtually been abandoned, drug-eluting stents have
been developed, and more potent antiplatelet agents
and other medical therapies have become available.
Furthermore, subsequent randomized studies such
as the FAME (Fractional Flow Reserve Versus Angi-
ography for Multivessel Evaluation) trial, although
performed in the stent era, were conducted in study
populations that do not align with guidelines for the
recommended use of coronary physiology to guide
decision making. Mean FFR in FAME was 0.71, while
FFR in DEFINE-FLAIR and iFR-SWEDEHEART
studies was close to the 0.80 cutoff, which is in
agreement with all other contemporary registries
and trials (8–10).
In the FAME trial, 513 lesions were deferred in 509
patients. At 2 years, 1.8% of patients had presentedDownloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGA
For personal use only. No other uses withouwith MI, and 10.4% required repeat revascularization
(19). In the FAME II trial, 166 registry patients (those
with FFR >0.80) were followed up. At 2 years, 9% of
patients had reached the primary endpoint. Looking
at the components of the primary endpoint, the
mortality rate was 1.2%, the MI rate 5.4%, and the
urgent revascularization rate 5.4% (16). Ahn et al.
(20) enrolled 5,846 patients in a prospective multi-
center study from 2009 to 2015 who had revascu-
larization guided by FFR (6,468 deferred lesions,
2,165 treated lesions). In this study, the risk for
cardiac events in deferred lesions, at a medianL - Hospital Prof Dr Fernando Fonseca from ClinicalKey.com by Elsevier on January 24, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
TABLE 5 Outcomes in the Overall Deferred Population According to Clinical Presentation
(Stable Angina Pectoris Versus Acute Coronary Syndrome) and Effect Modiﬁcation by
Physiological Technique
SAP
(n ¼ 1,675)
ACS
(n ¼ 440)
SAP vs. ACS
Unadjusted HR
(95% CI)
p
Value
Interaction
p Value
MACE 3.64 (61) 5.91 (26) 0.62 (0.39–0.99) 0.04
FFR 3.42 (27) 6.42 (14) 0.52 (0.27–1.00) 0.46
iFR 3.84 (34) 5.41 (12) 0.74 (0.38–1.42)
All-cause death 0.66 (11) 1.36 (6) 0.50 (0.19–1.36) 0.17
FFR 0.51 (4) 0.92 (2) 0.57 (0.10–3.13) 0.83
iFR 0.79 (7) 1.80 (4) 0.46 (0.13–1.57)
Cardiovascular death 0.18 (3) 0.45 (2) 0.41 (0.07–2.45) 0.33
FFR 0.00 (0) 0.46 (1)
iFR 0.34 (3) 0.45 (1) 0.78 (0.08–7.52)
Noncardiovascular
death
0.48 (8) 0.91 (4) 0.55 (0.16–1.82) 0.32
FFR 0.51 (4) 0.46 (1) 1.14 (0.13–10.24) 0.38
iFR 0.45 (4) 1.35 (3) 0.35 (0.08–1.56)
Myocardial infarction 0.90 (15) 2.50 (11) 0.34 (0.16–0.76) 0.01
FFR 0.89 (7) 2.75 (6) 0.28 (0.09–0.88) 0.64
iFR 0.90 (8) 2.25 (5) 0.42 (0.14–1.27)
Urgent revascularization 2.87 (48) 3.64 (16) 0.81 (0.46–1.43) 0.47
FFR 2.78 (22) 5.05 (11) 0.56 (0.27–1.16) 0.15
iFR 2.94 (26) 2.25 (5) 1.36 (0.52–3.53)
Values are % (n), unless otherwise indicated.
Abbreviations as in Tables 1 and 3.
FIGURE 4 Cumulat
Instantaneous Wave
Shown is the cumula
clinical presentation
free ratio (iFR) (righ
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Downloaded for Anofollow-up of 1.9 years, was linearly associated with
FFR values. When FFR was >0.70, the higher the
FFR value, the lower the incidence of cardiac events.
However, contemporary evidence supporting the
safety of FFR-based revascularization deferral isive Risk for Primary Endpoint (Major Adverse Cardiac Events) by Clinical P
-Free Ratio in the Deferred Population
tive risk for the composite of death from any cause, nonfatal myocardial infarc
with either stable angina pectoris (SAP) or acute coronary syndrome (ACS). D
t) are displayed.
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ical trials comparing outcomes in patients with ACS
compared with those with SAP.
DEFERRAL OF REVASCULARIZATION WITH EITHER
FFR OR iFR. The recently published DEFINE-FLAIR
and iFR-SWEDEHEART trials demonstrated that
iFR is noninferior to FFR in terms of clinical out-
comes associated with ischemia-driven revasculari-
zation (6,7). These trials provide the ﬁrst
opportunity to assess the validity of PCI deferral
with a pressure-derived index of stenosis severity
other than FFR. Of note, both studies consistently
demonstrated that fewer stenoses were deemed
hemodynamically signiﬁcant when iFR was used. As
this implies a higher rate of PCI deferral when iFR
is used as a diagnostic tool, comparing the out-
comes of patients who had iFR or FFR determined
PCI deferral is an objective of the utmost clinical
importance.
Overall, iFR and FFR are equally safe in deferring
revascularization, with event rates in our study of
4.12% and 4.05%, respectively (fully adjusted HR:
1.13; 95% CI: 0.72 to 1.79; p ¼ 0.60). These event rates,
at 1-year follow-up, are virtually one-half of those
reported for deferred patients in the DEFER trial (8%)
(3), reﬂecting the evolution of interventional and
medical therapy.
DEFERRAL OF REVASCULARIZATION IN PATIENTS
WITH ACS. The evidence supporting the safety of
deferral of PCI in patients with ACS on the basis ofresentation in Patients Assessed With Fractional Flow Reserve and
tion, or unplanned revascularization at 1 year, stratiﬁed according to
ata for fractional ﬂow reserve (FFR) (left) and instantaneous wave-
rnando Fonseca from ClinicalKey.com by Elsevier on January 24, 2019.
 ©2019. Elsevier Inc. All rights reserved.
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1447pressure-derived measurements is limited. The
conclusions of the DEFER trial, based on patients
with SAP, are therefore not applicable in contem-
porary clinical practice, in which ACS is a very
common indication for PCI. A substudy of the FAME
trial documented a higher prevalence of 2-year
MACE in 150 patients with ACS who had
physiology-guided PCI performed (21.3%), compared
with 359 patients with SAP included in the trial
(16.4%); importantly, that study did not report
separately the outcomes of deferred patients ac-
cording to clinical presentation (21). Recent ran-
domized trials addressing the safety of FFR-guided
revascularization of nonculprit stenoses in patients
with ACS and multivessel disease (11,12) have
focused only on the ACS subset, not comparing the
long-term outcomes with patients with SAP when
revascularization is deferred on the basis of FFR
(2,16). Furthermore, these trials included small
numbers of patients presenting with non–ST-
segment elevation MI, therefore contributing to the
paucity of data on this important topic. A further
limitation is that much evidence in this population
comes from observational data rather than ran-
domized clinical trials.
The present analysis conﬁrms that among pa-
tients who had revascularization deferred, those
presenting with ACS had a higher 1-year MACE rate
than those presenting with SAP (5.91% vs. 3.64%;
fully adjusted HR: 0.61; 95% CI: 0.38 to 0.99;
p ¼ 0.04) (Table 3). These ﬁndings are in agreement
with recently reported studies (13,14). Hakeem et al.
(14) found that FFR-based deferral of PCI in patients
with ACS was associated with a more than 2-fold
increase in the combined endpoint of MI or target
vessel revascularization at 3.4-year follow-up
compared with patients with SAP (23% vs. 11%,
respectively, p < 0.0001). Masrani Mehta et al. (13)
reported similar ﬁndings in a retrospective analysis
of a series of 674 patients, of whom 334 presented
with ACS. At a mean follow-up of 4.5 years, patients
with ACS had a signiﬁcantly higher MACE rate
than those with SAP (32% vs. 23%, respectively,
p ¼ 0.02). Lee et al. (15) reported, as part of a
prospective, international registry on FFR use, the
long-term outcomes (mean 2.1 years) after FFR-
based deferral of revascularization in 1,596 pa-
tients, of whom 301 presented with ACS. Deferral of
revascularization in nonculprit stenoses in patients
with ACS (n ¼ 409) was associated with a more than
2-fold increase in MACE compared with deferral of
stenoses in patients with SAP (adjusted HR: 2.97;
95% CI: 1.33 to 7.17; p ¼ 0.026). ClinicalDownloaded for Anonymous User (n/a) at CONSORTIUM OF PORTUGA
For personal use only. No other uses withoupresentation with ACS was identiﬁed in a multi-
variate Cox model as the most powerful indepen-
dent predictor of MACE after FFR-based
intervention deferral (adjusted HR: 2.74; 95% CI:
1.13 to 6.64; p ¼ 0.026). In contrast, our ﬁndings are
not concordant with those obtained in the pooled
population of 2 separate registries, including 1,983
patients, of whom 533 presented with ACS (22). At
1-year follow-up, FFR-based deferral was associated
with similar MACE rates in patients presenting with
ACS and SAP (8.0% vs. 8.5% with ACS and SAP,
respectively; p ¼ 0.83). Of note, MACE rates in that
registry were markedly higher than in our study,
particularly in patients with SAP (8.5% vs. 3.6% in
our study).
INFLUENCE OF CLINICAL PRESENTATION ON THE
SAFETY OF PRESSURE-DERIVED INDEXES OF
STENOSIS SEVERITY. Whether the observed higher
event rates among patients with ACS are due to their
inherent higher risk or to inadequate stenosis
assessment with pressure guidewires is unclear. From
contemporary trial data (23) patients presenting with
ACS have increased cardiovascular risk after stabili-
zation, with respective 1-year rates of MI and death of
5.8% and 2.4%.
In our analysis, we found that MACE in deferred
patients with ACS were driven largely by coronary
revascularization, although both MI and death also
contributed. This might provide indirect support for
the concept that in patients with ACS, pressure-
based indexes do not consistently identify the ste-
noses for which revascularization can be safely de-
ferred. Furthermore, other studies have reported
repeat revascularization as an important contributor
to MACE in patients presenting with ACS who had
revascularization deferred on the grounds of FFR
interrogation (13–15). As we did not assess the
characteristics of the atheromatous plaques in
nonculprit vessels in patients with ACS, an
increased risk attributable to vulnerable lesions in
these patients cannot be ruled out. Such risk might
be ampliﬁed by the presence of systemic inﬂam-
mation, which has been documented in patients
with ACS (24).
The excess of risk for physiology-based stenosis
deferral in patients with ACS may reﬂect the sub-
stantially different physiological conditions found in
these patients from those in patients with SAP.
Although FFR has been extensively validated as a
clinical tool in patients with SAP, its value in patients
with ACS is less well described. Microcirculatory
vasodilation during hyperemia can be transiently
blunted in the acute phase of ACS, affecting alsoL - Hospital Prof Dr Fernando Fonseca from ClinicalKey.com by Elsevier on January 24, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
PERSPECTIVES
WHAT IS KNOWN? DEFINE-FLAIR and iFR-
SWEDEHEART are the largest coronary physiology
clinical outcome trials ever conducted. Within the
trials, overall MACE rates at 1 year were similar for
both iFR- and FFR-guided populations. However, the
clinical outcomes of patients who had coronary
revascularization deferred on the basis of iFR or FFR
measurements, and the inﬂuence of clinical presen-
tation (SAP and ACS) on outcomes, are unknown.
WHAT IS NEW? Despite a higher rate of deferral
with iFR, clinical outcomes for both iFR- and FFR-
deferred populations were similar at 1 year. This in-
dicates that deferral of coronary revascularization by
either iFR or FFR methods is equally safe. However,
deferral of patients with ACS was associated with a
signiﬁcant increase in event rates at 1 year compared
with patients with SAP.
WHAT IS NEXT? Reporting of longer term clinical
outcomes from the DEFINE-FLAIR and iFR-
SWEDEHEART trials are awaited. Furthermore, ana-
lyses of key substudy populations of clinical interest
are ongoing.
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Downloaded for Anomyocardial territories remote to those subtended by
nonculprit stenoses (25). We explored whether iFR or
FFR resulted in better long-term outcomes of stenosis
deferral in patients with ACS. However, the negative
outcome associated with ACS presentation on 1-year
outcomes after revascularization deferral was not
signiﬁcantly inﬂuenced by the use of either iFR or
FFR, even when the individual components of MACE
were analyzed separately. Numerically, we observed
higher rates of MACE in the ACS compared with SAP
cohort among patients deferred with FFR. This dif-
ference in rates was less pronounced in patients de-
ferred with iFR.
STUDY LIMITATIONS. This was a nonrandomized
subset of 2 prospective randomized trials, but the
results have been fully adjusted for baseline clinical
characteristics. Both iFR and FFR are continuous
variables, which were reported and acted in a
dichotomous manner (i.e., treat or do not treat if
below or above a threshold), and therefore relevant
clinical information is omitted from the decision-
making process. In DEFINE-FLAIR, both the patients
and the treating physicians remained blinded to
group assignments, whereas in iFR-SWEDEHEART,
both were aware of the group assignment.
CONCLUSIONS
Overall, deferral of revascularization is equally safe
with both iFR and FFR, with a low MACE rate of
approximately 4%. Lesions were more frequently
deferred when iFR was used to assess physiological
stenosis signiﬁcance. Deferral of patients with ACS is
associated with a signiﬁcant increase in event rates at
1 year compared with patients with SAP.nymous User (n/a) at CONSORTIUM OF PORTUGAL - Hospital Prof Dr Fe
For personal use only. No other uses without permission. CopyrightADDRESS FOR CORRESPONDENCE: Dr. Justin E.
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